---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-002921"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2021-07-13T23:59:59+00:00"
generated_at: "2026-06-30T05:37:29.457557+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M

## Summary
- Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.
- Authorized shares decreased from 50B to 33,333,334; par value unchanged at $0.0001.
- Effective July 12, 2021; temporary ticker PMCBD for 20 business days, then revert to PMCB.
- CEO states split is a necessary step before Nasdaq listing and to support financing.
- No fractional shares issued; proportionate voting power unaffected; rounding up to whole share.

## SEC filing metadata
- accession: 0001683168-21-002921
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2021-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/0001683168-21-002921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316821002921/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-002921
- JSON: https://secwatch.observer/filing/0001683168-21-002921.json
- Plain text: https://secwatch.observer/filing/0001683168-21-002921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.